Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003 Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003
Here is the original post:
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
Recommendation and review posted by Fredricko
